Volume 1.15 | Aug 31

Dermal Cell News 1.15 August 31, 2015
Dermal Cell News
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  DCN on Twitter
A Caveolin-Dependent and PI3K/AKT-Independent Role of PTEN in β-Catenin Transcriptional Activity
The authors showed that loss of PTEN in epithelial and melanocytic cell lines induced the nuclear localization and transcriptional activation of β-catenin independent of the PI3K–AKT–GSK3β axis. The absence of PTEN led to caveolin-1-dependent β-catenin transcriptional modulation in vitro, cooperated with NRASQ61K to initiate melanomagenesis in vivo and induced efficient metastasis formation associated with E-cadherin internalization. [Nat Commun] Full Article
Weekend-Free Culture hPSCs with mTeSR™1 or TeSR™-E8™
PUBLICATIONS (Ranked by impact factor of the journal)

IFNλ Stimulates MxA Production in Human Dermal Fibroblasts via a MAPK-Dependent STAT1-Independent Mechanism
Researchers revealed cell type-specific differences in interferon lambda (IFNλ) signaling and function in skin resident cells. In dermal fibroblasts, IFNλ induced the expression of MxA, a potent antiviral factor, but not other IFN signature genes as it does in primary keratinocytes. [J Invest Dermatol] Full Article

TLR3 Drives IRF6-Dependent IL-23p19 Expression and p19/EBI3 Heterodimer Formation in Keratinocytes
Investigators report that interferon regulatory factor 6 (IRF6) regulates a subset of toll-like receptor 3 (TLR3) responses in human keratinocytes, including the production of a novel interleukin (IL)-12 family heterodimer (p19/EBI3). [Immunol Cell Biol] Abstract

Dermal Fibroblast Expression of Stromal Cell-Derived Factor-1 (SDF-1) Promotes Epidermal Keratinocyte Proliferation in Normal and Diseased Skin
Scientists investigated the expression and function of a stromal cell-specific protein, SDF-1, in normal human skin and in the tissues of diseased skin. [Protein Cell] Abstract


Oxidative Stress-Induced Overexpression of miR-25: The Mechanism Underlying the Degeneration of Melanocytes in Vitiligo
Scientists found that microRNA (miR)-25 was increased in both serum and lesion samples from vitiligo patients, and its serum level was correlated with the activity of vitiligo. [Cell Death Differ] Abstract

Transcriptional Analysis of Vitiligo Skin Reveals the Alteration of WNT Pathway: A Promising Target for Repigmenting Vitiligo Patients
The authors found a significant increase in CXCL10 in non-depigmented and perilesional vitiligo skin compared to levels in healthy control skin; however, neither CXCL10 nor other immune factors were deregulated in depigmented vitiligo skin. [J Invest Dermatol] Abstract

Progression of Mouse Skin Carcinogenesis Is Associated with the Orchestrated Deregulation of miR-200 Family Members, miR-205 and Their Common Targets
The authors exploited a well-established multistage mouse skin carcinogenesis model in order to identify microRNAs consistently implicated in different stages of skin carcinogenesis. [Mol Carcinog] Abstract

Peroxiredoxin 6 Triggers Melanoma Cell Growth by Increasing Arachidonic Acid Dependent Lipid Signaling
Researchers investigated the functional role of peroxiredoxin 6 (PRDX6) in human melanoma cells. They showed that PRDX6 is strongly expressed in most melanoma cells and its expression levels are maintained in a post-transcriptional manner, particularly by EGFR-dependent signaling. [Biochem J] Abstract

HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade
Researchers showed that class I histone deacetylase (HDAC) inhibitors upregulated the expression of PD-L1 and, to a lesser degree, PD-L2 in melanomas. Evaluation of human and murine cell lines and patient tumors treated with a variety of HDAC inhibitors in vitro displayed upregulation of these ligands. [Cancer Immunol Res] Abstract

Learn More: Standardized Tools for Cancer Research
Exploring the Role of Interleukin-22 in Neurological and Autoimmune Disorders
Emerging evidence has identified interleukin-22 involvement in neurological diseases and autoimmune disorders such as Guillain-Barré Syndrome, multiple sclerosis, Alzheimer’s disease, encephalitis, inflammatory myopathies, myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, Sjogren’s syndrome, psoriasis and Crohn’s disease. [Int Immunopharmacol] Abstract

Visit our reviews page to see a complete list of reviews in the dermal cell research field.
NanoPass Technologies Will Present 8 Years of Clinical Experience with Its MicronJet600™ Device in the Coming Skin Vaccination Summit 2015 Meeting
NanoPass Technologies Ltd. announced it will be delivering two oral presentations on the company’s intradermal delivery device MicronJet600™ at the Skin Vaccination Summit in Lausanne, Switzerland on September 2-4. [Press release from NanoPass Technologies Ltd. (PRNewswire Associations LLC) discussing research to be presented at the Skin Vaccination Summit, Lausanne] Press Release

From our sponsor:
Optimize your ALDHbr cell detection with tissue-specific ALDEFLUOR™ protocols.
Watch the video.
Innovative Device Will Regenerate Skin Cells to Aid Wound Care
Avita Medical Ltd announced that it has forged a partnership with the University of Huddersfield to explore the mechanism of Regenerative Epithelial Suspension – to better understand its ability to effectively treat burns, hard-to-heal wounds and skin trauma. [University of Huddersfield] Press Release

Celprogen Introduces FolliStem™, an Ideal Product for Regrowth of Human Hair
Celprogen Inc. announced that they have developed a novel product FolliStem™ for Regrowth of human hair. FolliStem™ is manufactured from Adipose Derived Stem Cells that also contains STEMC8007 the human hair follicle stem cell stimulator. [Celprogen Inc. (BusinessWire)] Press Release

MicuRx Reports Positive Top-Line Results in Phase II Clinical Trial for Novel Antibiotic MRX-I in Complicated Skin and Soft Tissue Infections
MicuRx Pharmaceuticals, Inc. announced positive top-line results from the first Phase II clinical study for its lead drug candidate MRX-I. MRX-I is an oral oxazolidinone antibiotic designed to treat drug-resistant bacteria such as MRSA and VRE, while offering physicians and patients a safer and better tolerated therapeutic option than currently available oxazolidinone agents. [MicuRx Pharmaceuticals, Inc.] Press Release
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW European Molecular Biology Laboratory (EMBL) Conference: Cancer Genomics
November 1-4, 2015
Heidelberg, Germany

Visit our events page to see a complete list of events in the dermal cell community.
NEW Lab Technician I – Melanoma Metastasis (Fred Hutchinson Cancer Research Center)

NEW Postdoctoral Fellow – HMGA Chromatin Remodeling Proteins in Cancer and Stem Cell Biology (Johns Hopkins University School of Medicine)

Research Associate – Skin Inflammation and Carcinogenesis (Imperial College London)

Postdoctoral Scientist – Skin Microbiome (National Human Genome Research Institute)

Senior Manager Immunology – Immunology (Baxalta Innovations GmbH)

Assistant Professor – Cell Biology or Molecular and Cellular Mechanisms (Washington University School of Medicine)

PhD Position – Materials Engineering (IFP Energies Nouvelles)

Postdoctoral Fellow – Cancer Biology (University of Pennsylvania)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Dermal Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Dermal Cell News: Archives | Events | Contact Us